| The molecular basis of factor V and VIII procofactor activation RM Camire, MHA Bos Journal of Thrombosis and Haemostasis 7 (12), 1951-1961, 2009 | 119 | 2009 |
| High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor IM Rietveld, WM Lijfering, S le Cessie, MHA Bos, FR Rosendaal, ... Journal of Thrombosis and Haemostasis 17 (1), 99-109, 2019 | 106 | 2019 |
| Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity MC Kleinegris, MHA Bos, M Roest, Y Henskens, A ten Cate‐Hoek, ... Journal of Thrombosis and Haemostasis 12 (10), 1647-1657, 2014 | 90 | 2014 |
| A bipartite autoinhibitory region within the B-domain suppresses function in factor V MHA Bos, RM Camire Journal of Biological Chemistry 287 (31), 26342-26351, 2012 | 74 | 2012 |
| Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations MHA Bos, M Boltz, L St. Pierre, PP Masci, J De Jersey, MF Lavin, ... Blood, The Journal of the American Society of Hematology 114 (3), 686-692, 2009 | 61 | 2009 |
| Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7α-hydroxylase in cultured rat hepatocytes andin vivoin the rat SM Post, PJ Zoeteweij, MH Bos, EC de Wit, R Havinga, F Kuipers, ... Hepatology 30 (2), 491-500, 1999 | 59 | 1999 |
| Lipid levels and risk of venous thrombosis: results from the MEGA-study VM Morelli, WM Lijfering, MHA Bos, FR Rosendaal, SC Cannegieter European journal of epidemiology 32, 669-681, 2017 | 51 | 2017 |
| Blood coagulation factors V and VIII: molecular mechanisms of procofactor activation MHA Bos, RM Camire Journal of coagulation disorders 2 (2), 19, 2010 | 47 | 2010 |
| Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding M Schreuder, PH Reitsma, MHA Bos Journal of Thrombosis and Haemostasis 17 (8), 1229-1239, 2019 | 46 | 2019 |
| Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors D Verhoef, KM Visscher, CR Vosmeer, KL Cheung, PH Reitsma, ... Nature communications 8 (1), 528, 2017 | 45 | 2017 |
| Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ‐carboxylation of a human vitamin K‐dependent protein by the insect enzyme J Vatandoost, A Zomorodipour, M Sadeghizadeh, R Aliyari, MHA Bos, ... Biotechnology progress 28 (1), 45-51, 2012 | 44 | 2012 |
| Procoagulant adaptation of a blood coagulation prothrombinase-like enzyme complex in australian elapid venom MHA Bos, RM Camire Toxins 2 (6), 1554-1567, 2010 | 39 | 2010 |
| Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? MHA Bos, DWE Meijerman, C Van der Zwaan, K Mertens Journal of Thrombosis and Haemostasis 3 (3), 522-530, 2005 | 38 | 2005 |
| Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides MW Bunce, MHA Bos, S Krishnaswamy, RM Camire Journal of Biological Chemistry 288 (42), 30151-30160, 2013 | 37 | 2013 |
| Coagulopathy after hemorrhagic traumatic brain injury, an observational study of the incidence and prognosis JAN van Gent, TA van Essen, MHA Bos, SC Cannegieter, JTJM van Dijck, ... Acta neurochirurgica 162, 329-336, 2020 | 34 | 2020 |
| Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom CN Zdenek, C Hay, K Arbuckle, TNW Jackson, MHA Bos, B op den Brouw, ... Toxicology in Vitro 58, 97-109, 2019 | 34 | 2019 |
| Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors J Debono, MHA Bos, A Nouwens, L Ge, N Frank, HF Kwok, BG Fry Toxicology in Vitro 55, 62-74, 2019 | 34 | 2019 |
| Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial FA Orsi, JS Biedermann, MJHA Kruip, FJ van der Meer, FR Rosendaal, ... Journal of Thrombosis and Haemostasis 17 (2), 319-328, 2019 | 34 | 2019 |
| Objectives and design of BLEEDS: a cohort study to identify new risk factors and predictors for major bleeding during treatment with vitamin K antagonists N van Rein, WM Lijfering, MHA Bos, MH Herruer, HW Vermaas, ... PloS one 11 (12), e0164485, 2016 | 34 | 2016 |
| Basal but divergent: Clinical implications of differential coagulotoxicity in a clade of Asian vipers J Debono, MHA Bos, F Coimbra, L Ge, N Frank, HF Kwok, BG Fry Toxicology in vitro 58, 195-206, 2019 | 32 | 2019 |
